{"abstract":"The Food and Drug Administration (FDA) is proposing to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is proposing minor revisions to an existing classification regulation and also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.","action":"Proposed amendment; proposed order; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/11/12/2026-23005.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"864","title":21}],"citation":"91 FR 72825","comment_url":"http://www.regulations.gov/commenton/FDA-2026-N-12508-0001","comments_close_on":"2027-01-11","correction_of":null,"corrections":[],"dates":"Either electronic or written comments on the proposed order must be submitted by January 11, 2027. Please see section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.","disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-12508"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":2,"comment_start_date":"2026-11-12","updated_at":"2026-11-14T00:56:41.902-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-12508-0001","allow_late_comments":false,"id":"FDA-2026-N-12508-0001","comment_end_date":"2027-01-12","regulations_dot_gov_open_for_comment":true}],"supporting_documents_count":0,"id":"FDA-2026-N-12508","title":"Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product"}],"document_number":"2026-23005","effective_on":null,"end_page":72837,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/11/12/2026-23005.xml","html_url":"https://www.federalregister.gov/documents/2026/11/12/2026-23005/hematology-and-pathology-devices-reclassification-of-immunohistochemistry-test-systems-for-use-with","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-23005?publication_date=2026-11-12","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-11-12/2026-23005/mods.xml","not_received_for_publication":null,"page_length":13,"page_views":{"count":1358,"last_updated":"2026-11-18 14:15:03 -0500"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-11-12/pdf/2026-23005.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-23005.pdf?1794318321","publication_date":"2026-11-12","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/11/12/2026-23005.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":2,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-12508","supporting_documents_count":0,"docket_id":"FDA-2026-N-12508","document_id":"FDA-2026-N-12508-0001","regulation_id_number":null,"title":"Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product","checked_regulationsdotgov_at":"2026-11-15T09:55:04Z"},"regulations_dot_gov_url":"http://www.regulations.gov/commenton/FDA-2026-N-12508-0001","significant":null,"signing_date":null,"start_page":72825,"subtype":null,"title":"Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product","toc_doc":"Reclassification of Immunohistochemistry Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product","toc_subject":"Hematology and Pathology Devices","topics":["Blood","Medical devices","Packaging and containers"],"type":"Proposed Rule","volume":91}